DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Treanda (Bendamustine Hydrochloride) - Current Clinical Trials

 
 



Treanda Related Clinical Trials

Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia [Active, not recruiting]

Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma [Recruiting]

Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma [Active, not recruiting]

Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL) [Terminated]

Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL) [Recruiting]

Ph 1b, Carfilzomib, Bendamustine, Dexamethasone in Multiple Myeloma [Recruiting]

Fludarabine, Bendamustine and Rituximab Conditioning for Patients With Lymphoid Malignancies [Completed]

Bendamustine and Radiation Therapy in Treating Patients With Brain Metastases Caused by Solid Tumors [Active, not recruiting]

Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma [Recruiting]

Bendamustine in Acute Lymphoblastic Leukemia/Lymphoma (ALL) [Withdrawn]

Bendamustine + Rituximab in Older Patients With Previously Untreated Diffuse Large B-cell Lymphoma [Active, not recruiting]

Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-Cell Lymphomas [Recruiting]

Fludarabine, Bendamustine, and Rituximab (FBR) in Chronic Lymphocytic Leukemia (CLL) [Active, not recruiting]

Bendamustine and Bevacizumab for Advanced Cancers [Completed]

Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma [Active, not recruiting]

A Randomized, Double-Blind and Placebo-Controlled Study of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) [Active, not recruiting]

Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma [Recruiting]

Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma [Not yet recruiting]

Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) [Completed]

Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL) [Completed]

Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy [Active, not recruiting]

Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors [Active, not recruiting]

Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL) [Terminated]

Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma [Completed]

Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma [Recruiting]

Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas [Active, not recruiting]

Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer [Completed]

Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL) [Withdrawn]

Bendamustine in the Treatment of Chinese Patients With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab Treatment [Active, not recruiting]

Capecitabine + Bendamustine in Women With Pretreated Locally Advanced or Metastatic Her2-negative Breast Cancer [Active, not recruiting]

Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia [Completed]

Peripheral Blood Stem Cell (PBSC) Mobilization in Patients With Relapsed Lymphoma Treated With Bendamustine [Active, not recruiting]

Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies [Recruiting]

Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma [Completed]

Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma [Recruiting]

Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma [Recruiting]

CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma [Recruiting]

CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma [Recruiting]

Bendamustine, Cytarabine, Etoposide and Melphalan (BeEAM) as Conditioning for Autologous Stem Cell Transplant (ASCT) in Aggressive Non Hodgkin's Lymphoma (NHL). [Active, not recruiting]

Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL) [Active, not recruiting]

Bendamustine Hydrochloride and Idarubicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia or Myelodysplastic Syndrome [Completed]

Bendamustine in Acute Leukemia and MDS [Terminated]

Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma [Active, not recruiting]

Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma [Active, not recruiting]

Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma [Recruiting]

A Phase 1/2 Study of Lenalidomide in Combination With Bendamustine in Relapsed and Primary Refractory Hodgkin Lymphoma [Active, not recruiting]

Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma [Completed]

Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma [Active, not recruiting]

Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma [Active, not recruiting]

A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma [Recruiting]

Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies [Recruiting]

Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL) [Recruiting]

Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma [Not yet recruiting]

Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer [Recruiting]

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma [Active, not recruiting]

PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab [Withdrawn]

Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab [Terminated]

Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Active, not recruiting]

Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma [Recruiting]

Study Bendamustine Concurrent Whole Brain Radiation Brain Metastases From Solid Tumors [Terminated]

Ribomustin in the First Line Therapy of Chronic Lymphocytic Leukemia [Active, not recruiting]

Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL) [Active, not recruiting]

Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL) [Completed]

SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL) [Completed]

Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma [Recruiting]

Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL [Active, not recruiting]

Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell Lymphoma [Completed]

Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy [Active, not recruiting]

CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies [Recruiting]

Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma [Recruiting]

Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL) [Completed]

Bendamustine Plus Rituximab Versus CHOP Plus Rituximab [Completed]

Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study [Active, not recruiting]

Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia [Completed]

Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia [Withdrawn]

Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma [Withdrawn]

Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant [Recruiting]

Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma [Completed]

A Phase II Study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma [Active, not recruiting]

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma. [Active, not recruiting]

Bendamustine, Prednisone and VelcadeŽ for First-line Treatment of Patients With Symptomatic Multiple Myeloma [Recruiting]

Study of Bendamustine, Velcade and Dexamethasone in the Treatment of Elderly Patients With Multiple Myeloma [Active, not recruiting]

Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma [Active, not recruiting]

Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma [Recruiting]

Bendamustine Plus Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma [Completed]

Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma [Active, not recruiting]

Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL) [Recruiting]

A Multicentre Phase I-II Study to Investigate the Combination of Bendamustine With Weekly Paclitaxel as First or Second Line Therapy in Patients With Metastatic Breast Cancer [Completed]

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia [Recruiting]

Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma [Active, not recruiting]

Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma [Recruiting]

Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer [Active, not recruiting]

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Active, not recruiting]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017